Research programme: cathepsin S inhibitors - Medivir AB
Alternative Names: CD-1; MIV-247; MV-57471Latest Information Update: 14 Jul 2015
At a glance
- Originator Medivir AB
- Class Small molecules
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Asthma; Autoimmune disorders; Hypersensitivity; Multiple sclerosis; Neuropathic pain; Rheumatoid arthritis
Most Recent Events
- 16 Jun 2015 Discontinued - Preclinical for Neuropathic pain (Combination therapy) in Sweden (PO)
- 16 Jun 2015 Discontinued - Preclinical for Neuropathic pain (Monotherapy) in Sweden (PO)
- 15 Oct 2014 Preclinical development is ongoing in Neuropathic pain (Monotherapy) in Sweden